InnoPharmax Inc. (TPEX:4172)

InnoPharmax Statistics

Total Valuation

InnoPharmax has a market cap or net worth of TWD 1.86 billion. The enterprise value is 1.59 billion.

Market Cap	1.86B
Enterprise Value	1.59B

Important Dates

The next estimated earnings date is Friday, August 8, 2025.

Earnings Date	Aug 8, 2025
Ex-Dividend Date	n/a

Share Statistics

InnoPharmax has 107.58 million shares outstanding. The number of shares has increased by 5.83% in one year.

Current Share Class	107.58M
Shares Outstanding	107.58M
Shares Change (YoY)	+5.83%
Shares Change (QoQ)	+5.17%
Owned by Insiders (%)	1.88%
Owned by Institutions (%)	4.43%
Float	89.95M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	57.46
PB Ratio	3.08
P/TBV Ratio	3.11
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-16.01
EV / Sales	49.23
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-20.71

Financial Position

The company has a current ratio of 10.90, with a Debt / Equity ratio of 0.03.

Current Ratio	10.90
Quick Ratio	9.74
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.20
Interest Coverage	-312.64

Financial Efficiency

Return on equity (ROE) is -18.41% and return on invested capital (ROIC) is -10.76%.

Return on Equity (ROE)	-18.41%
Return on Assets (ROA)	-10.37%
Return on Invested Capital (ROIC)	-10.76%
Return on Capital Employed (ROCE)	-15.90%
Revenue Per Employee	949,912
Profits Per Employee	-2.92M
Employee Count	34
Asset Turnover	0.06
Inventory Turnover	0.51

Taxes

In the past 12 months, InnoPharmax has paid 2.32 million in taxes.

Income Tax	2.32M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -31.22% in the last 52 weeks. The beta is 0.08, so InnoPharmax's price volatility has been lower than the market average.

Beta (5Y)	0.08
52-Week Price Change	-31.22%
50-Day Moving Average	17.18
200-Day Moving Average	17.01
Relative Strength Index (RSI)	52.28
Average Volume (20 Days)	70,530

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, InnoPharmax had revenue of TWD 32.30 million and -99.29 million in losses. Loss per share was -1.02.

Revenue	32.30M
Gross Profit	20.76M
Operating Income	-95.98M
Pretax Income	-96.97M
Net Income	-99.29M
EBITDA	-93.92M
EBIT	-95.98M
Loss Per Share	-1.02

Balance Sheet

The company has 281.23 million in cash and 15.39 million in debt, giving a net cash position of 265.84 million or 2.47 per share.

Cash & Cash Equivalents	281.23M
Total Debt	15.39M
Net Cash	265.84M
Net Cash Per Share	2.47
Equity (Book Value)	602.85M
Book Value Per Share	5.60
Working Capital	290.89M

Cash Flow

In the last 12 months, operating cash flow was -76.22 million and capital expenditures -527,000, giving a free cash flow of -76.75 million.

Operating Cash Flow	-76.22M
Capital Expenditures	-527,000
Free Cash Flow	-76.75M
FCF Per Share	-0.71

Margins

Gross Margin	64.29%
Operating Margin	-297.18%
Pretax Margin	-300.23%
Profit Margin	n/a
EBITDA Margin	-290.81%
EBIT Margin	-297.18%
FCF Margin	n/a

Dividends & Yields

InnoPharmax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.83%
Shareholder Yield	n/a
Earnings Yield	-5.35%
FCF Yield	-4.14%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

InnoPharmax has an Altman Z-Score of 33.54 and a Piotroski F-Score of 3.

Altman Z-Score	33.54
Piotroski F-Score	3